These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 25291660

  • 41. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC, Barrett PH, Ooi EM, Ji J, Chan DT, Watts GF.
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [Abstract] [Full Text] [Related]

  • 42. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Mar; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 43. The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.
    Drouin-Chartier JP, Hogue JC, Tremblay AJ, Bergeron J, Lamarche B, Couture P.
    Lipids Health Dis; 2017 Jun 15; 16(1):119. PubMed ID: 28619117
    [Abstract] [Full Text] [Related]

  • 44. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M.
    Arterioscler Thromb Vasc Biol; 2004 Aug 15; 24(8):1448-53. PubMed ID: 15166014
    [Abstract] [Full Text] [Related]

  • 45. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS.
    Metabolism; 2001 Jan 15; 50(1):112-9. PubMed ID: 11172484
    [Abstract] [Full Text] [Related]

  • 46. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S.
    Arterioscler Thromb Vasc Biol; 2015 Oct 15; 35(10):2254-9. PubMed ID: 26293463
    [Abstract] [Full Text] [Related]

  • 47. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women.
    Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, Borel P, Portugal H, Pauli AM, Vialettes B, Lairon D.
    J Clin Endocrinol Metab; 1999 Jan 15; 84(1):184-91. PubMed ID: 9920081
    [Abstract] [Full Text] [Related]

  • 48. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
    Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, R Barrett PH.
    Circulation; 2017 Jan 24; 135(4):338-351. PubMed ID: 27941065
    [Abstract] [Full Text] [Related]

  • 49. Sources and properties of triglyceride-rich lipoproteins containing apoB-48 and apoB-100 in postprandial blood plasma of patients with primary combined hyperlipidemia.
    Kovar J, Havel RJ.
    J Lipid Res; 2002 Jul 24; 43(7):1026-34. PubMed ID: 12091486
    [Abstract] [Full Text] [Related]

  • 50. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S, Serban MC, Banach M.
    J Cardiovasc Pharmacol Ther; 2015 Mar 24; 20(2):157-68. PubMed ID: 24938457
    [Abstract] [Full Text] [Related]

  • 51. Postprandial lipemia associates with liver fat content.
    Matikainen N, Mänttäri S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-Järvinen H, Taskinen MR.
    J Clin Endocrinol Metab; 2007 Aug 24; 92(8):3052-9. PubMed ID: 17488790
    [Abstract] [Full Text] [Related]

  • 52. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 24; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 53. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
    Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD.
    Clin Sci (Lond); 2014 May 24; 126(9):679-84. PubMed ID: 24308640
    [Abstract] [Full Text] [Related]

  • 54. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
    Brouwers MC, van Greevenbroek MM, Troutt JS, Bonner Freeman A, Lu A, Schaper NC, Konrad RJ, Stehouwer CD.
    Clin Sci (Lond); 2011 Nov 24; 121(9):397-403. PubMed ID: 21539517
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG.
    Clin Chem; 2002 Feb 24; 48(2):278-83. PubMed ID: 11805008
    [Abstract] [Full Text] [Related]

  • 57. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S, Xu RX, Zhang Y, Guo YL, Zhu CG, Liu G, Dong Q, Li JJ.
    J Endocrinol Invest; 2015 Dec 24; 38(12):1291-9. PubMed ID: 26003826
    [Abstract] [Full Text] [Related]

  • 58. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W, Le May C, Cariou B.
    Trends Endocrinol Metab; 2018 Jun 24; 29(6):420-434. PubMed ID: 29665987
    [Abstract] [Full Text] [Related]

  • 59. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.
    Arterioscler Thromb Vasc Biol; 2014 Jun 24; 34(6):1171-8. PubMed ID: 24675665
    [Abstract] [Full Text] [Related]

  • 60. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.
    Matikainen N, Taskinen MR, Stennabb S, Lundbom N, Hakkarainen A, Vaaralahti K, Raivio T.
    Eur J Endocrinol; 2012 Mar 24; 166(3):487-92. PubMed ID: 22190000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.